Calcium pidolate in direct compression tablet formulations imposes a dosage mass constraint because the salt supplies approximately 13.5% w/w elemental calcium; a film-coated tablet delivering 135 mg elemental calcium therefore requires about 1,000 mg of API per unit, which places the formulation close to the upper mass range for single-tablet administration. The API fraction in the compression blend typically falls between 60% and 75% w/w, with microcrystalline cellulose 102 at 20–30% w/w, crospovidone at 3–4% w/w as disintegrant, pregelatinized starch at 5–8% w/w as dry binder, and magnesium stearate at 0.5–1.0% w/w as lubricant. Direct compression requires the incoming API batch to be specified for particle size distribution, bulk density, and loss on drying, because moisture above 1.0% w/w and D50 values outside the 100–180 µm band have been observed on rotary tablet presses to produce sticking to upper punches and weight variation exceeding USP <905> acceptance thresholds. Blending is performed in a bin blender at 10–12 rpm for 15–20 min after geometric dilution of magnesium stearate; over-lubrication beyond 5 min at full speed is avoided because the resulting hydrophobic film reduces tablet hardness and slows disintegration. Compression on a 27-station rotary press with a 19.0 × 9.0 mm capsule-shaped punch set is run at 25–45 rpm with precompression force 3–5 kN and main compression force 12–18 kN; ejection force above 1.5 kN or turret speed above 50 rpm has been associated with capping at the tablet band in batches where the API moisture was not controlled below 1.0% w/w. Tablet cores are aqueous film-coated with an HPMC/PEG 3350 system to a 2.5–3.5% w/w weight gain in a perforated pan at 45–55°C inlet air; the coated tablets are tested for disintegration per Ph. Eur. 2.9.1 and dissolution per USP <711> in 0.1 N hydrochloric acid, with Q = 80% at 30 min. The terminal finished product is an oral film-coated tablet for calcium supplementation, with compliance to Ph. Eur. 2.9.5, USP <905>, ICH Q3D, and 21 CFR 211.

Which Dry Granulation Route Reduces Dosator Sticking in Calcium Pidolate Capsules?

For capsule filling of calcium pidolate, the direct powder blend may display marginal flow and high dusting losses because the API has a relatively high aqueous solubility and irregular crystal habit; roller compaction followed by 0.8 mm oscillating sieve milling is therefore used to produce a granulate with bulk density 0.55–0.70 g/mL and Carr index below 25. The capsule fill formulation contains calcium pidolate 65–75% w/w, microcrystalline cellulose 102 15–25% w/w, sodium starch glycolate 2–4% w/w, colloidal silicon dioxide 0.5–1.0% w/w, and magnesium stearate 0.5–1.0% w/w; if the capsule body-fill weight is 700 mg and the API fraction is 70% w/w, each size 0 hard capsule delivers approximately 66 mg elemental calcium based on the 13.5% w/w calcium equivalence. The dry granulate is filled on an intermittent tamping-pin capsule machine rather than a dosator machine because calcium pidolate compacts are prone to sticking on polished dosator pins at relative humidity above 60%; tamping-pin stations 1–4 are set with pin heights from 12 mm to 18 mm to build a plug density of 0.75–0.85 g/mL. Capsule fill weight RSD is maintained below 2.0% by controlling hopper relative humidity at 35–40% and by using 18/8 stainless steel contact parts with electropolished surfaces. The filled capsules are checked for weight uniformity per Ph. Eur. 2.9.5, content uniformity per USP <905>, dissolution per USP <711> in water at 37°C with Q = 75% at 45 min, and microbial limits per Ph. Eur. 2.6.12 and 2.6.13. The terminal finished product is a hard capsule for oral calcium supplementation; gelatin capsules may require a desiccant package insert because moisture migration from the shell into a hygroscopic granulate can raise capsule brittleness at low humidity below 30% RH, while HPMC capsules are selected when the fill formulation contains residual moisture above 4% w/w. Compliance with 21 CFR 211 and ICH Q1A stability testing is standard for this dosage form.

In single-dose oral granule presentations intended for pediatric, geriatric, or dysphagic patients, calcium pidolate is processed by fluid-bed top-spray granulation to produce free-flowing granules that disperse rapidly in 50–100 mL water. The formulation delivers target elemental calcium doses of 40–135 mg per sachet by adjusting the API proportion between 30% and 55% w/w; mannitol occupies 25–50% w/w, povidone K30 2–4% w/w as binder, croscarmellose sodium 1–3% w/w as disintegrant, and a non-reducing flavouring system 0.5–1.5% w/w. The binder solution is prepared as 5% w/w povidone K30 in purified water; top-spray fluid-bed granulation is run with inlet air temperature 55–65°C, product temperature 30–35°C, spray rate 10–20 g/min per kg batch, and atomising air pressure 1.5–2.5 bar. Granules are dried to a loss on drying below 1.5% w/w and sieved through a 1.0 mm screen; fines below 0.15 mm are not recycled if they exceed 15% w/w because they raise sachet dusting and fill weight variation. Single-dose sachets are filled using an auger filler with net weight control at ±3% relative standard deviation; the sealing jaws are set to 140–160°C for 0.5–1.0 s for a polyethylene/aluminium/polyethylene terephthalate laminate. Finished granules are tested for uniformity of mass per Ph. Eur. 2.9.5, water content per Ph. Eur. 2.2.32, microbial quality per Ph. Eur. 2.6.12 and 2.6.13, and elemental impurities per ICH Q3D. The terminal finished product is an oral granule for solution or suspension in single-dose sachets.

When calcium pidolate is converted into an effervescent oral dosage form, the manufacturing environment and granulation route are determined by the acid-base reaction between citric acid and sodium bicarbonate, which proceeds if moisture is not kept below 0.5% w/w in the blend. The effervescent formulation contains calcium pidolate 30–45% w/w, anhydrous citric acid 15–22% w/w, sodium bicarbonate 25–35% w/w, sodium carbonate 0–5% w/w, PEG 6000 2–3% w/w as lubricant and protective coating, and sucralose 0.1–0.2% w/w. Because any residual water initiates premature effervescent reaction, the mixture is dry granulated by roller compaction at 30–50 bar hydraulic pressure and milled through a 0.8 mm screen before compression at 15–25 kN on a rotary tablet press. The compression suite is held at ≤20% RH and 18–22°C; if the granulate is exposed to relative humidity above 25% during compression, sodium bicarbonate decomposes slowly and tablet hardness can decline by 30% within 4 h, a failure mode controlled by installing desiccant rotor units on hoppers and limiting batch dwell time to 60 min. Effervescent tablets are tested for disintegration in 200 mL water at 15–25°C within 3 min per Ph. Eur. 2.9.1, and weight uniformity per Ph. Eur. 2.9.5. A unit containing 300 mg calcium pidolate delivers approximately 40 mg elemental calcium when dispersed; the terminal finished product is an effervescent tablet or single-dose effervescent granule for oral solution, manufactured under 21 CFR 211.

Injectable Solution Quality Attributes and Terminal Sterilization Boundaries

Calcium pidolate injection is formulated as a sterile, preservative-free aqueous solution in borosilicate glass ampoules or vials. A 10% w/v calcium pidolate solution delivers approximately 13.5 mg/mL elemental calcium; if the clinical presentation is 10 mL ampoules, each unit contains 1.0 g calcium pidolate and 135 mg elemental calcium. The formulation includes water for injection q.s., pidolic acid or dilute hydrochloric acid for pH adjustment to 5.5–7.5, and nitrogen headspace purging to reduce oxidative discoloration. The solution is prepared in a stainless steel 316L mixing vessel at 25–40°C, stirred at 100–150 rpm under nitrogen until fully dissolved; the batch is then filtered through a 0.45 µm prefilter followed by a 0.22 µm sterilising-grade polyvinylidene fluoride or polyethersulfone membrane filter. Filling is performed under Grade A laminar airflow in a Grade B cleanroom with a peristaltic or rotary piston filler; ampoules are flame-sealed and then terminally sterilized by steam autoclaving at 121°C for 15 min. Terminal sterilization of calcium pidolate solutions requires a pre-established load pattern because the heat capacity of large-volume containers shifts the F₀ value; validation with biological indicators Geobacillus stearothermophilus at 10⁶ CFU per unit and temperature mapping with 12–16 thermocouples are standard. Finished product tests include visible particulate inspection per USP <790>, sub-visible particulate count per Ph. Eur. 2.9.19 and USP <788>, and bacterial endotoxin per Ph. Eur. 2.6.14. Calcium pidolate should not be compounded with phosphate or carbonate salts in unbuffered concentrates because calcium phosphate/carbonate precipitation occurs at pH above 7.5; compatibility with bicarbonate-containing diluents requires calcium solubility modelling. The terminal finished product is a sterile solution for injection administered after dilution or as slow intravenous injection; manufacturing compliance falls under 21 CFR 210/211, ICH Q3D, and current pharmacopoeial monographs for parenterals.

When Calcium Pidolate Is Diluted Into Infusion Solutions for Institutional Compounding

When calcium pidolate injection is diluted into 0.9% w/v sodium chloride or 5% w/v glucose infusion bags in hospital cleanrooms, the primary process risks are calcium-phosphate precipitation and sub-visible particle formation from syringe needle coring. The addition ratio during compounding is typically controlled to maintain elemental calcium concentration between 0.025 and 0.05 mmol/mL (1.0–2.0 mg elemental calcium per mL) in the final infusion; this corresponds to 7.4–14.8 mg calcium pidolate per mL of infusion based on the 13.5% w/w calcium content. Compounding is performed in an ISO Class 5 laminar airflow workbench within an ISO Class 7 buffer room per USP <797>; syringes are filled using 18G blunt fill needles, and the injection port is disinfected with sterile 70% isopropanol for 10–15 s. The admixture is passed through an in-line 0.22 µm filter during transfer where the container allows; visual inspection for precipitates is performed against a black and white background before release. The terminal dosage form is a ready-to-use IV infusion bag with beyond-use dating assigned by USP <797> risk category: 9 days at 2–8°C for low-risk compounded sterile preparations if prepared with a closed system transfer device, or 24 h at ambient temperature if not. Incompatibility boundaries are explicit: calcium pidolate must not be added to phosphate-containing parenteral nutrition admixtures without first calculating the CaHPO₄ solubility product using the final amino acid and glucose concentrations, because precipitation is not always visible below 5 µm. Published data for calcium pidolate compatibility with certain multi-chamber parenteral nutrition products is limited; therefore, site-specific stability studies are required before routine use.